Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
REX1, RNA exonuclease 1 homolog pseudogene (LOC100129276; ENSG00000230936) is classified as a pseudogene, meaning it is a genetic sequence similar to a protein-coding gene but is non-functional and does not produce a functional protein. There is no evidence for a direct biological or therapeutic role. It is not considered a drug target, biomarker, or contributor to any known disease process. The locus's nomenclature aligns it with the REXO1/REX1 exonuclease family, but, as a pseudogene, it is not involved in RNA processing or any exonuclease activity. This entry is not a real or functional molecular target; it is explicitly classified as a pseudogene in gene databases. There is no canonical abbreviation in widespread scientific use. Multiple RNase-related pseudogenes with similar names (such as REXO1L1P, REXO1L3P) exist, which can cause confusion, but ENSG00000230936/LOC100129276 specifically denotes a pseudogene. In summary, REX1, RNA exonuclease 1 homolog pseudogene is best classified as a non-functional pseudogene with no current evidence for use as a therapeutic target, disease biomarker, or drug interaction partner.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on REX1, RNA exonuclease 1 homolog pseudogene.